Evogene Ltd (EVGN)
NASDAQ: EVGNIndustrialsAgricultural ChemicalsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
EVGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.71M
- EPS (TTM)
- -$1.55
- Dividend yield
- None
- 52-week range
- 0.25 – 1.26
- Day range
- 0.2891 – 0.341
- Volume / Avg
- 62.77K / 1.40M
- Beta
- —
- Shares outstanding
- 18.05M
52-week range
EVGN stock today
On Nov 20, EVGN ended the session at $0.3162, adding $0.0032 (1.02%), versus the S&P 500's 3.70% decline. Trading was light, with 62.77K shares changing hands, about 4% of the average daily volume. At this level, EVGN sits near the bottom of its 52-week range of $0.25 to $1.26: 74.9% below the high and 26.5% above the low.
Evogene has posted a net loss over the last twelve months (EPS of -$1.55), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Evogene
Company profileEvogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine.
- Sector
- Industrials
- Industry
- Agricultural Chemicals
- CEO
- Mr. Ofer Haviv CPA
- Headquarters
- Rehovot
- Employees
- 38
- Website
- evogene.com
Financial highlights
Full financialsIn fiscal 2025, Evogene generated $3.9 million in revenue, down 30.9% from fiscal 2024, its first annual decline since 2021. Evogene reported a net loss of $8.5 million, compared with a loss of $16.5 million a year earlier. Gross margin was -6.3% (down from 57.3%) and operating margin -364.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $3.85M | $5.58M | $2.98M | $1.68M | $930.00K |
| Growth | -30.91% | +87.02% | +78.03% | +80.11% | -10.58% |
| Net income | $-8.48M | $-16.48M | $-23.88M | $-26.64M | $-27.79M |
| EPS (diluted) | $1.08 | $-2.90 | $-5.20 | $-6.44 | $-0.69 |
Analyst forecast
ForecastConsensus (1 analysts)
strong_buy
Avg. price target
$2.15+579.95%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 19, 2026
- EPS actual vs est.
- $-0.17 vs $-0.19
- Surprise
- +10.53%
EVGN news
All EVGN newsEvogene peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SNESSenesTech Inc. | 0.69 | +6.15% | $4.71M | vs EVGN |
| FRTTFort Technology Inc. | 0.47 | -9.79% | $7.14M | vs EVGN |
| NXTSNexentis Technologies Inc. | 1.58 | -7.06% | $1.05M | vs EVGN |
| BIOXBioceres Crop Solutions Corp. | 0.173 | -5.41% | $11.04M | vs EVGN |
| ICLICL Group Ltd. | 4.08 | -1.45% | — | vs EVGN |
| UANCVR Partners LP | 95.09 | -0.88% | — | vs EVGN |
| AVDAmerican Vanguard Corporation | 0.68 | -1.48% | $20.10M | vs EVGN |
| CBUSCibus Inc. Class A | 1.21 | -1.63% | $92.73M | vs EVGN |
Indexes, lists and sector
Evogene stock FAQ
What is Evogene's stock price today?
EVGN last traded at $0.3162 as of Nov 20, 4:00 PM EST, up 1.02% on the day. Prices are delayed at least 15 minutes.
Who is Evogene's CEO?
Mr. Ofer Haviv CPA is the chief executive officer of Evogene Ltd, which has about 38 employees.
What is the EVGN 52-week high?
The 52-week high for EVGN is $1.26 and the 52-week low is $0.25. The stock is currently 74.9% below its high.